Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies

Abstract

Background: Relapsed/metastatic salivary gland carcinomas (SGC) have a wide diversity of histologic subtypes associated with variable clinical aggressiveness and response to local and systemic therapies. We queried whether comprehensive genomic profiling could define the tumor subtypes and uncover clinically relevant genomic alterations, revealing new routes to targeted therapies for patients with relapsed and metastatic disease.Patients and Methods: From a series of 85,686 clinical cases, DNA was extracted from 40 µm of FFPE sections for 623 consecutive SGC. CGP was performed on hybridization-captured, adaptor ligation-based libraries (mean coverage depth >500X) for up to 315 cancer-related genes. Tumor mutational burden (TMB) was determined on 1.1 Mb of sequenced DNA. All classes of alterations, base substitutions, short insertions/deletions, copy number changes and rearrangements/fusions were determined simultaneously.Results: The clinically more indolent SGC including adenoid cystic carcinoma (ACC), acinic cell carcinoma (AciCC), polymorphous low grade adenocarcinoma (PLGA), mammary analogue secretory carcinoma (MASC), and epithelial-myoepithelial carcinomas have significantly fewer genomic alterations (GA), TP53 mutations, and lower TMB than the typically more aggressive SGCs including mucoepidermoid carcinoma (MEC), salivary duct carcinoma (SDC), adenocarcinoma, not otherwise specified (AD-NOS), carcinoma NOS (CA-NOS) and carcinoma ex pleomorphic adenoma (Ca ex PA). The more aggressive SGCs are commonly driven by ERBB2 PI3K pathway GAs. Additional targetable GAs are frequently seen.Conclusions: Genomic profiling of SGCs demonstrates important differences between traditionally indolent and aggressive cancers. These differences may provide therapeutic options in the future.

http://ift.tt/2wdkxGT